<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02595840</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT-Nr. 2014-001983-36</org_study_id>
    <nct_id>NCT02595840</nct_id>
  </id_info>
  <brief_title>Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)</brief_title>
  <acronym>Trans-MARBLE</acronym>
  <official_title>Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universität Duisburg-Essen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy of afatinib maintenance with pemetrexed maintenance following
      induction therapy with platinum/ pemetrexed in patients with metastatic EGFR mutated
      non-small-cell lung cancer progressing after first-line treatment with afatinib as first
      tyrosine kinase inhibitor with respect to progression-free survival
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have progressed after first-line treatment with afatinib as first tyrosine
      kinase inhibitor (TKI) will be screened while they are receiving second-line (induction)
      treatment consisting of cisplatin / carboplatin plus pemetrexed given in 21-day cycles.
      Patients who do not progress (i.e. complete or partial response, or stable disease - CR, PR
      or SD) after completion of at least three and not more than four chemotherapy cycles will be
      randomized (1:1 ratio) to receive maintenance therapy with either afatinib (40 mg/d or last
      tolerated dose during first-line treatment with afatinib as first TKI) or pemetrexed (500
      mg/m2 or 375 mg/m2 if dose reduction was required every 21 days) until disease progression or
      treatment discontinuation because of patient decision or toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility
  </why_stopped>
  <start_date type="Actual">November 25, 2015</start_date>
  <completion_date type="Actual">November 20, 2017</completion_date>
  <primary_completion_date type="Actual">November 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, open-label, phase II study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival in relation to exploratory biomarkers</measure>
    <time_frame>until progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in relation to exploratory biomarkers</measure>
    <time_frame>continuous assessment</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Assessed every 6 weeks for 24 weeks, then every 9 weeks</time_frame>
    <description>Objective response rate, clinical benefit rate (RECIST 1.1)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Non-small-cell Lung Cancer With Somatic EGFR Mutations</condition>
  <arm_group>
    <arm_group_label>Arm A: Afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Afatinib 40 mg/d (30, or 20 mg/d in case of dose reduction during 1st line treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pemetrexed 500 mg/m2 (375 mg/m² in case of dose reduction during induction therapy) i.v. on d1 of each 21-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <arm_group_label>Arm A: Afatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Arm B: Pemetrexed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participation in the AIO-TRK-0114 (MARBLE) study (EudraCT-No. 2014-001983-36)

          2. Written informed consent

        Exclusion Criteria:

        1. Patients who do not meet the inclusion criterial of the AIO-TRK-0114 (MARBLE) study
        (EudraCT-No. 2014-001983-36)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2015</study_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universität Duisburg-Essen</investigator_affiliation>
    <investigator_full_name>Martin Schuler, Prof. Dr. med.</investigator_full_name>
    <investigator_title>Director, Department of Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

